Uploaded July 2023 | Updated September 2026, 1 week ago
Insilico Medicine founder and CEO Alex Zhavoronkov gives a tour of Insilico’s AI-run robotics lab and describes a program to find new targets for colon cancer.
🤖 Watch as autonomous guided vehicles take cell lines through microplating, imaging, incubation, and next generation sequencing.
🤖 Collected data is fed into the AI, which selects the targets which will be validated using real compounds that AI selects.
Insilico Medicine founder and CEO Alex Zhavoronkov gives a tour of Insilico’s AI-run robotics lab and describes a program to find new targets for colon cancer.
🤖 Watch as autonomous guided vehicles take cell lines through microplating, imaging, incubation, and next generation sequencing.
🤖 Collected data is fed into the AI, which selects the targets which will be validated using real compounds that AI selects.
![[Nature Communications] Oral ENPP1 Inhibitor as Next Generation STING Modulator for Solid Tumors](https://i.ytimg.com/vi/R9wa1NeqVZg/mqdefault.jpg "[Nature Communications] Oral ENPP1 Inhibitor as Next Generation STING Modulator for Solid Tumors
Cold tumors are cancers with little to no immune cell infiltration. They lack the ability to activate the immune system, leaving patients with few options. Recently, Insilico Medicine announced breakthrough findings in immune oncology therapy targeting ENPP1, published in Nature Communications, a leading peer reviewed journal.")
